SıradakiSonraki rehber
Hekimler için Yapay Zeka Klinik Karar Desteği
Endüstriler
Toplum REHBERİ
FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply.
The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.
Clinical decision support software provides information or recommendations to support healthcare decisions. FDA’s guidance explains how the agency assesses software functions under the applicable statutory criteria. Some functions may be excluded from the device definition when they meet specific conditions, including that a health professional can independently review the basis for recommendations. Other functions, including certain patient-specific analyses or device functions, may remain subject to oversight. The assessment is about what a particular software function does, its intended user, and how the output is used. A product can contain multiple functions with different regulatory status. A tool that presents evidence for a clinician to review is not automatically treated the same as software that directs diagnosis or treatment. FDA guidance also notes that functions intended for patients or caregivers may be assessed differently from clinician-facing support. Manufacturers should define each function and provide information that supports independent review where relevant. Clinicians should understand what inputs and evidence support a recommendation, the intended population, and limitations. A generated explanation is not itself proof of the underlying basis. Check current FDA guidance and product labeling for the specific function. This guide summarizes concepts and does not determine regulatory status for a product. Preserve examples of intended use and evidence that support the analysis, and revisit it when users, claims, or outputs change. Keep patient-facing and clinician-facing functions distinct in requirements and documentation.
Yıkıcı ve günlük yapay zeka zararları, kimin riskleri anladığı ve kimin harekete geçebileceğine bağlıdır.
Kamu ve profesyonel okuryazarlık, güçlü bir güvenlik politikasının politik olarak mümkün olup olmadığını şekillendirir.
Açık açıklamalar abartılı reklamların, laboratuvar halkla ilişkiler uygulamalarının ve belirsiz etik tiyatrosunun etkisi altına girmeyi azaltır.
Decision-support products increasingly use machine learning and generative models, creating new questions about explainability and how clinicians review evidence. FDA guidance is updated as laws and technology change. Developers should monitor current agency materials and preserve a function-level analysis. Care teams need training to interpret outputs and should retain clinical judgment even when a tool is authorized. Developers should design interfaces that make the evidence and limitations easy to inspect, not merely generate a plausible explanation. Monitor outcomes and user feedback.
A clinician reviews sources and rationale behind a recommendation before acting.
A software team separates administrative reminders from patient-specific treatment recommendations.
A hospital confirms whether a function is intended for health professionals or patients.
A developer maps the product’s intended use to the criteria in current FDA guidance.
Yetenekleri artırırken varoluşsal riski bilim kurgu olarak ele almak.
Yüzey ürün güvenliğini yüksek özerklik altında hizalamayla karıştırmak.
İngilizce olmayan ve uzman olmayan izleyici kitlesini yalnızca düşük kaliteli kaynaklarla bırakmak.
Ürün zararları, yanlış kullanım ve kontrol kaybı/yanlış hizalama risklerini ayırın.
Hangi kanıtların zaman çizelgeleri ve ciddiyet konusundaki görüşünüzü değiştireceğini sorun.
Pazarlama iddiaları yerine birincil kaynakları ve somut değerlendirmeleri tercih edin.
Tek bir eylem yolu belirleyin: kariyer, politika, finansman veya beceriler; yalnızca farkındalık değil.
Free newsletter
Three verified AI stories every weekday morning, written in plain English. Free forever, no ads.
One email each weekday. Unsubscribe in one click. We never sell or share your address.
Test yourself
Instant feedback on every answer, and a shareable certificate with a verifiable ID once you pass a course.
Support free AI education. AI Understanding is a 501(c)(3) nonprofit — no ads, no paywall, ever. Make a donation
FDA’s Clinical Decision Support Software guidance explains when software functions may be regulated as medical devices and when a non-device CDS exclusion may apply. The analysis depends on the function, intended user, and ability of a health professional to independently review the basis for recommendations. These distinctions require function-specific review, not assumptions based on a product’s “CDS” label.
Regulatory analysis depends on the function and how it is used.
Regulatory assessment is not necessarily product-wide and uniform.
Function-specific documentation supports assessment and use.
CDS supports decisions and does not replace professional review.
Öğrenmeye devam et
Bu konu için daha fazla rehber seçildi
SıradakiSonraki rehber
Hekimler için Yapay Zeka Klinik Karar Desteği
Endüstriler